DK3381461T3 - Peptider og fremgangsmåder til anvendelse deraf - Google Patents

Peptider og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3381461T3
DK3381461T3 DK18160178.2T DK18160178T DK3381461T3 DK 3381461 T3 DK3381461 T3 DK 3381461T3 DK 18160178 T DK18160178 T DK 18160178T DK 3381461 T3 DK3381461 T3 DK 3381461T3
Authority
DK
Denmark
Prior art keywords
peptides
procedures
Prior art date
Application number
DK18160178.2T
Other languages
Danish (da)
English (en)
Inventor
Soren Mogelsvang
Cohava Gelber
Original Assignee
Serpin Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serpin Pharma Llc filed Critical Serpin Pharma Llc
Application granted granted Critical
Publication of DK3381461T3 publication Critical patent/DK3381461T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK18160178.2T 2012-01-09 2013-01-07 Peptider og fremgangsmåder til anvendelse deraf DK3381461T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584517P 2012-01-09 2012-01-09
US201261699571P 2012-09-11 2012-09-11
EP13700808.2A EP2802338B1 (en) 2012-01-09 2013-01-07 Peptides and methods of using same

Publications (1)

Publication Number Publication Date
DK3381461T3 true DK3381461T3 (da) 2021-05-17

Family

ID=47595077

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18160178.2T DK3381461T3 (da) 2012-01-09 2013-01-07 Peptider og fremgangsmåder til anvendelse deraf
DK13700808.2T DK2802338T3 (en) 2012-01-09 2013-01-07 PEPTIDES AND PROCEDURES FOR USE THEREOF

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13700808.2T DK2802338T3 (en) 2012-01-09 2013-01-07 PEPTIDES AND PROCEDURES FOR USE THEREOF

Country Status (10)

Country Link
US (6) US9951104B2 (enExample)
EP (2) EP2802338B1 (enExample)
JP (1) JP6416627B2 (enExample)
AU (3) AU2013208293B2 (enExample)
CA (2) CA3077804C (enExample)
DK (2) DK3381461T3 (enExample)
ES (2) ES2676028T3 (enExample)
IL (1) IL233481A0 (enExample)
MX (1) MX365403B (enExample)
WO (1) WO2013106273A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106273A2 (en) 2012-01-09 2013-07-18 Serpin Pharma, Llc Peptides and methods of using same
WO2014197524A2 (en) * 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
EP3019188B1 (en) 2013-07-08 2022-03-09 The University of Utah Research Foundation A peptide and the use thereof in the treatment of inflammatory disorders
IL295025A (en) * 2014-09-16 2022-09-01 Bioincept Llc Preparations and methods for the treatment of acute radiation syndrome
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3265064A4 (en) * 2015-03-04 2018-11-07 Microvention, Inc. Drug delivery device
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017040287A1 (en) * 2015-08-28 2017-03-09 Serpin Pharma, Llc Methods for treatment of diseases
CA3004095A1 (en) * 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019212031A1 (ja) * 2018-05-02 2019-11-07 国立大学法人新潟大学 ペプチド及びその使用
WO2022010939A2 (en) * 2020-07-06 2022-01-13 Serpin Pharma, Llc Peptides and methods of using the same

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
FI81498C (fi) 1987-01-13 1990-11-12 Biocon Oy Kirurgiska material och instrument.
US5270171A (en) * 1987-03-06 1993-12-14 Boris Cercek Cancer-associated SCM-recognition factor, preparation and method of use
US5580561A (en) * 1987-03-06 1996-12-03 Cercek; Boris Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
EP0667786B1 (en) 1992-08-27 2004-01-21 Deakin Research Limited Retro-, inverso-, and retro-inverso synthetic peptide analogues
WO1994005265A1 (en) 1992-09-10 1994-03-17 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
AU7435296A (en) 1995-10-16 1997-05-07 Dana-Farber Cancer Institute Novel expression vectors and methods of use
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
WO1999055564A1 (en) 1998-04-24 1999-11-04 Univ Florida Materials and methods for gene therapy
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
WO2003089011A1 (en) 2002-04-19 2003-10-30 University Of Florida rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
EP2520654B8 (en) 2003-08-26 2017-04-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US20090023643A1 (en) 2004-01-13 2009-01-22 Vasogenix Pharmaceuticals, Inc. Methods For Treating Acute Myocardial Infarction By Administering Calcitonin Gene Related Peptide And Compositions Containing The Same
DE602005013670D1 (de) * 2004-05-21 2009-05-14 Inst Systems Biology Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
BRPI0621081A2 (pt) 2005-12-23 2011-11-29 Vital Health Sciences Pty Ltd método de modulação de uma ou mais citocinas imuno-reguladoras, uso de um ou mais derivados de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos, método de inibição de uma resposta inflamatória e/ou de estimulação de uma resposta anti-inflamatória, método de tratamento e/ou de profilaxia de distúbios imunológicos, distúrbios inflamatórios e/ou distúrbios proliferativos celulares, agente imuno-modulador, agente anti-inflamatório ou agente anti-cáncer e um ou mais derivado de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos
AU2007221177A1 (en) 2006-02-28 2007-09-07 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
US20090203602A1 (en) * 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
US8623830B2 (en) 2006-09-12 2014-01-07 Beth Israel Deaconess Medical Center, Inc. Compositions containing α-1-antitrypsin and methods for use
HRP20150330T1 (hr) 2007-08-30 2015-06-19 Curedm Group Holdings, Llc Pripravci i postupci uporabe prostaniäśnog peptida za stanice otoäśiä†a i njegovih analoga
US8758761B2 (en) 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US7923253B2 (en) * 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
WO2011109768A2 (en) 2010-03-04 2011-09-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating cardiac conditions
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
US9005615B2 (en) 2010-05-06 2015-04-14 The Feinstein Institute For Medical Research Methods for treatment of inflammatory diseases
WO2013106273A2 (en) 2012-01-09 2013-07-18 Serpin Pharma, Llc Peptides and methods of using same
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2014197524A2 (en) 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
KR20160146242A (ko) 2015-06-12 2016-12-21 현대자동차주식회사 터보차저 엔진의 재순환 밸브 구동 장치 및 방법
WO2017040287A1 (en) 2015-08-28 2017-03-09 Serpin Pharma, Llc Methods for treatment of diseases

Also Published As

Publication number Publication date
US20210188912A1 (en) 2021-06-24
ES2676028T3 (es) 2018-07-16
CA3077804C (en) 2023-07-25
IL233481A0 (en) 2014-08-31
US9951104B2 (en) 2018-04-24
US20170029465A9 (en) 2017-02-02
JP2015504073A (ja) 2015-02-05
DK2802338T3 (en) 2018-06-14
AU2017258892A1 (en) 2017-11-30
WO2013106273A2 (en) 2013-07-18
AU2019253814B2 (en) 2022-03-10
US20130274187A1 (en) 2013-10-17
AU2013208293B2 (en) 2017-08-10
US8975224B2 (en) 2015-03-10
EP3381461B1 (en) 2021-03-10
WO2013106273A3 (en) 2013-12-19
US20140378372A1 (en) 2014-12-25
CA2859777C (en) 2020-06-30
CA3077804A1 (en) 2013-07-18
AU2017258892B2 (en) 2019-11-14
EP2802338A2 (en) 2014-11-19
ES2871544T3 (es) 2021-10-29
CA2859777A1 (en) 2013-07-18
US20250346632A1 (en) 2025-11-13
AU2019253814A1 (en) 2019-11-14
US12291581B2 (en) 2025-05-06
EP3381461A1 (en) 2018-10-03
US10214562B2 (en) 2019-02-26
US20200017550A1 (en) 2020-01-16
MX2014007799A (es) 2014-10-24
US10899797B2 (en) 2021-01-26
AU2013208293A2 (en) 2016-01-28
EP2802338B1 (en) 2018-03-07
JP6416627B2 (ja) 2018-10-31
US20150133375A1 (en) 2015-05-14
HK1203161A1 (en) 2015-10-23
AU2013208293A1 (en) 2014-06-26
BR112014016734A2 (pt) 2020-10-27
MX365403B (es) 2019-05-31

Similar Documents

Publication Publication Date Title
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK3381461T3 (da) Peptider og fremgangsmåder til anvendelse deraf
DK2854883T3 (da) Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3196022T3 (da) Trykningssystem og fremgangsmåde
DK2909427T3 (da) Tætningsanordning og -fremgangsmåde
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2726092T3 (da) Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf
DK2906684T3 (da) T-celle-modificerende forbindelser og anvendelser deraf
DK2838900T3 (da) Forbindelser og fremgangsmåder til antiviral behandling
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3282708T3 (da) Anordning og fremgangsmåde til billedbehandling
DK2817287T3 (da) Trialkyl kationisk lipid og metoder til anvendelse deraf
DK2743669T3 (da) Fejldetekteringssystem og tilhørende fremgangsmåde
DK2928533T3 (da) Medicinske slanger og fremgangsmåder til fremstilling
DK3379339T3 (da) Procespatron og billeddannende indretning
DK2584921T3 (da) Sondeernæringspakninger og fremgangsmåder til anvendelse deraf
DK3930322T3 (da) Fremgangsmåder og anordninger til kodning
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK2908661T3 (da) Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf